Time to disease progression (appearance of 1+ new lesions or increase >or= to 20% of sum of the longest diameters of target lesions compared to the lower sum of maximum diameters recorded since the start of the study). Month 3, 6, 9, 12, 15, 18, 21 and 24 [clinicaltrials_resource:7617f410e00fba9b8bd7d1ce647fba5e]
120mg administered via deep subcutaneous injection every 28 days for up to 24 months or until disease progression.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Time to disease progression (appearance of 1+ new lesions or increase >or= to 20% of sum of the longest diameters of target lesions compared to the lower sum of maximum diameters recorded since the start of the study). Month 3, 6, 9, 12, 15, 18, 21 and 24 [clinicaltrials_resource:7617f410e00fba9b8bd7d1ce647fba5e]
120mg administered via deep subcutaneous injection every 28 days for up to 24 months or until disease progression.
Bio2RDF identifier
7617f410e00fba9b8bd7d1ce647fba5e
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:7617f410e00fba9b8bd7d1ce647fba5e
measure [clinicaltrials_vocabulary:measure]
Time to disease progression (a ...... since the start of the study).
time frame [clinicaltrials_vocabulary:time-frame]
Month 3, 6, 9, 12, 15, 18, 21 and 24
description
120mg administered via deep su ...... or until disease progression.
identifier
clinicaltrials_resource:7617f410e00fba9b8bd7d1ce647fba5e
title
Time to disease progression (a ...... 3, 6, 9, 12, 15, 18, 21 and 24
@en
type
label
Time to disease progression (a ...... 7f410e00fba9b8bd7d1ce647fba5e]
@en